# 2025-15796: FDA Guides Cancer Trial Survival Stats: Smarter Studies Ahead

2025-15796, Approaches to Assessment of Overall Survival in Oncology Clinical Trials; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-19 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-15796
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-15796
- Title: Approaches to Assessment of Overall Survival in Oncology Clinical Trials; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 40367
- Published: 2025-08-19
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Guides Cancer Trial Survival Stats: Smarter Studies Ahead

## Summary

The FDA just dropped a draft guide to help drug makers figure out the best ways to measure how long cancer patients live during clinical trials. This guide mainly focuses on smart ways to analyze survival when it’s not the main goal of the study. If you’re in the cancer drug world, this could change how you design trials and report results—so keep an eye out and get ready to adapt!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Approaches to Assessment of Overall Survival in Oncology Clinical Trials." The purpose of this draft guidance is to provide recommendations to sponsors on the assessment of overall survival in randomized oncology clinical trials conducted to support marketing approval of drugs and biological products, with an emphasis on the analysis of overall survival as a prespecified safety endpoint. While the draft guidance discusses situations in which it is appropriate to consider overall survival for the primary endpoint, this draft guidance primarily focuses on statistical or design considerations when overall survival is not the primary endpoint.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2025-15796 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/19/2025-15796/approaches-to-assessment-of-overall-survival-in-oncology-clinical-trials-draft-guidance-for-industry)
- [2025-15796 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-19/pdf/2025-15796.pdf)

## Related
- [Previous: 2025-15795, Request for Information Concerning the Capital Investment Grants Program](https://policyrisk.com/federal-register/2025-15795)
- [Next: 2025-15797, Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical…](https://policyrisk.com/federal-register/2025-15797)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-15796 (as of 2026-06-08).